Skoulidis et al., 2010
|
KrasG12D
|
15% tumour penetrance with long latency; 100% PDAC |
KrasG12D, Brca2Tr/Wt
|
Accelerated tumourigenesis with an increase in tumour penetrance at 30%; 100% PDAC |
KrasG12D, Brca2Tr/F11
|
Pancreatic insufficiency; some tumours develop but with long latency; 100% PDAC |
KrasG12D, Tp53R270H, Brca2Wt/Wt
|
Highly penetrant tumour formation with a median survival of 168 days; 100% PDAC |
KrasG12D, Tp53R270H, Brca2Tr/Wt
|
Accelerated tumourigenesis, median survival 143 days, in comparison to Brca2Wt; 100% PDAC |
KrasG12D, Tp53R270H, Brca2Tr/F11
|
Further acceleration of tumourigenesis, median survival 84 days, all tumours showed regions of PDAC development with noted regions of Acinar histology in 18% of cases |
Rowley et al., 2011 |
KrasG12D
|
61% tumour penetrance with median survival 406 days |
KrasG12D, Brca2F11/Wt
|
66% tumour penetrance with median survival 366 days‐ similar to Brca2Wt
|
KrasG12D, Brca2F11/F11
|
Pancreatic insufficiency; 13% tumour penetrance with long latency |
Brca2Wt/Wt
|
No tumour formation |
Brca2F11/Wt
|
No tumour formation |
Brca2F11/F11
|
No tumour formation |
Tp53F2‐10/F2‐10, Brca2Wt/Wt
|
Low tumour penetrance with acinar histology |
Tp53F2‐10/F2‐10, Brca2F11/Wt
|
Similar penetrance of tumour formation to Brca2Wt but with the associated histology of Brca2F11/F11
|
Tp53F2‐10/F2‐10, Brca2F11/F11
|
Increased tumour penetrance and acceleration of tumour formation in comparison to Brca2Wt
of Brca2F11/Wt
Mixed histology: PDAC 40%, Acinar 15%, high‐grade undifferentiated 35%, remainder mucinous tumours. Median survival 300 days. |
Feldmann et al., 2011
|
Brca2F11/F11
|
Pancreatic insufficiency; development of PDAC but with incomplete penetrance (∼15%) at 15 months. Median survival 454 days. |
Tp53R172H, Brca2F11/F11
|
Pancreatic insufficiency; highly penetrant PDAC formation (100%) at 15 months. Median survival 375 days. |